NCT05325775View on ClinicalTrials.gov

Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

March 30, 2022

Primary Completion Date

March 4, 2023

Study Completion Date

March 4, 2023

Conditions
Post-menopausal Vasomotor Symptoms
Interventions
DRUG

ACER-801 50 mg BID

50 mg BID (twice daily)

DRUG

ACER-801 100 mg BID

100 mg BID (twice daily)

DRUG

ACER-801 200 mg BID

200 mg BID (twice daily)

DRUG

Placebo

Placebo

Trial Locations (1)

53095

Spaulding Clinical Research, West Bend

Sponsors
All Listed Sponsors
lead

Acer Therapeutics Inc.

INDUSTRY

NCT05325775 - Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause | Biotech Hunter | Biotech Hunter